搜索结果: 1-11 共查到“知识库 肿瘤学 Immunotherapy”相关记录11条 . 查询时间(0.098 秒)
![](http://www.firstlight.cn/upload/imgfile/20234/14/202341415416365.png)
Journal for ImmunoTherapy of Cancer丨罗敏/卢智刚团队报道瘤内注射激活STING的纳米疫苗提高抗肿瘤免疫效果(图)
卢智刚团队 肿瘤免疫 生物医学研究院
2023/4/14
整合含有天然免疫刺激分子的纳米制剂、以及个性化新抗原筛选技术,使肿瘤疫苗在临床测试展现了令人瞩目的有效性。新一代的肿瘤疫苗与CAR技术﹑免疫检查点干预成为免疫治疗中重要的三大板块。然而,在很多病人中,T细胞无法通过肿瘤屏障进入瘤内,导致对多种免疫治疗的不敏感;因此促进T细胞进入肿瘤,逆转肿瘤微环境成为提高免疫治疗效果的重要步。
![](http://www.firstlight.cn/upload/imgfile/20234/14/2023414173145998.jpg)
徐建青、张晓燕教授团队《Journal for ImmunoTherapy of Cancer》报道一种全新的、肿瘤微环境激活杀伤的CAR-T,有潜力成为不同实体瘤有效治疗手段(图)
张晓燕教授 生物医学研究院 实体瘤 CAR-T疗法
2023/4/14
近年来,CAR-T疗法治疗血液源性肿瘤效果显著,然而在针对实体瘤的临床研究中却遭遇重大挑战。目前CAR-T均为靶点激活杀伤,而肿瘤靶点通常也在正常组织低表达,进而产生“on-target, off-tumor”现象、诱生炎症因子风暴、中枢神经毒性等,给CAR-T治疗带来严重的安全隐患。肿瘤细胞的异质性进一步导致靶点激活杀伤有效性受到挑战。即目前的靶点激活杀伤的CAR-T技术在在治疗实体瘤中,安全性...
![](http://www.firstlight.cn/upload/imgfile/20234/17/20234179531356.jpg)
许杰课题组《Journal for Immunotherapy of Cancer》揭示THADA在驱动PD-L1高尔基体驻留中的作用以及肿瘤免疫靶标价值(图)
许杰课题组 癌细胞 免疫检查点
2023/4/17
癌细胞中程序性死亡配体1(PD-L1)的异常上调抑制T细胞介导的细胞毒性,但驱动和维持PD-L1表达的分子机制仍不完全清楚。PD-L1在肿瘤细胞内高尔基体等细胞器的驻留可能是影响抗体药物疗效的因素之一,但既往对其理解并不充分,使免疫检查点阻断疗法面临挑战。
New systemic therapies for metastatic melanoma – mapk inhibitors and immunotherapy
metastatic melanoma mapk inhibitors
2015/4/7
Metastatic melanoma has a poor prognosis and until recently systemic therapy was ineffective. Advances in the
understanding of tumour biology and immune regulation have led to the development of tar...
Immunotherapy of melanoma – past, present and future
past present future Immunotherapy melanoma
2015/3/18
Treatment of melanoma by immunotherapy remains a topic of much interest. Initial studies were based on stimulation of
immune responses by immunisation with whole cells or lysates of whole cells. Some...
Cancer immunotherapy aims to exploit and maximise the body’s
own immune system in order to target and destroy cancer cells.
The immune system is a complex and effective integrated
network of specia...
Immunotherapy of melanoma
melanoma Immunotherapy
2015/3/11
Melanoma is a cruel disease. The most recent Australian figures
indicate that over 8000 cases of melanoma were reported in
1997 and that approximately 900 people died of the disease
that year+
. O...
Dendritic cell biology and application for tumour immunotherapy
tumour immunotherapy Dendritic cell biology
2015/3/11
The dendritic cell (DC), an uncommon type of bone marrowderived leukocyte, is widely acknowledged as the most
effective antigen presenting cell (APC) and has the unique
capacity to initiate and cont...
APPLICATION OF GENETICALLY ENGINEERED TUMOR-SPECIFIC TH1 CELLS TO ADOPTIVE TUMOR IMMUNOTHERAPY
Carcinoembryonic antigen chimeric immunoglobulin T cell receptor DO11.10 gene transfer immunotherapy
2009/7/15
CD4+ Th cells, in particular IFN-γ-producing Th1 cells, play a critical role in the activation and maintenance of CD8+ Tc1 cells that are essential for tumor eradication. Recent identification of MHC ...
NOVEL APPROACH TO IMMUNOTHERAPY FOR EPITHELIAL CANCERS,BONE AND SOFT-TISSUE SARCOMAS
Apoptosis proteins caspase clinical trials cytotoxic T-lymphocytes epithelial cancers gastric cancer antigen osteosarcoma antigen
2009/7/15
The identification of tumor antigens recognized by cytotoxic T-lymphocytes and subsequent clinical trials using peptide immunization have shown tumor regression in advanced malignant melanoma patients...
Heat immunotherapy with heat shock protein expression by hyperthermia using magnetite nanoparticles
Heat shock proteins Hyperthermia Tumor immunity Magnetite
2009/7/15
Hyperthermia is a possible approach for cancer therapy. However, a major technical problem associated with the use of hyperthermia is the difficulty of heating the local tumor region to the intended t...